Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in AML and Allo-HCT Patients
NCT03678493Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2019
- Primary completion
- Feb 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fecal Microbiota Transplantation capsules in bacterial infection, viral infection, fungal infection and 1 more (4 arms), sponsored by Masonic Cancer Center. Primary endpoint: Efficacy of FMT in AML Patients and Allo-HCT Recipients - Number of Infections at 4 months. Started Sep 2019; status: completed.
02
Drugs
Fecal Microbiota Transplantation capsules
03
Conditions
bacterial infectionviral infectionfungal infectiongraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03678493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678493.